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Abstract
Paget’s disease of bone (PDB) is a skeletal disorder characterized by focal and disorganized increases in bone
turnover and overactive osteoclasts. The discovery of mutations in the SQSTM1/p62 gene in numerous patients has
identified protein p62 as an important modulator of bone turnover. In both precursors and mature osteoclasts, the
interaction between receptor activator of NF-B ligand (RANKL) and its receptor RANK results in signaling cascades
that ultimately activate transcription factors, particularly NF-B and NFATc1, promoting and regulating the
osteoclast differentiation, activity, and survival. As a scaffold with multiple protein-protein interaction motifs, p62 is
involved in virtually all the RANKL-activated osteoclast signaling pathways, along with being implicated in
numerous other cellular processes. The p62 adaptor protein is one of the functional links reported between RANKL
and TRAF6-mediated NF-B activation, and also plays a major role as a shuttling factor that targets
polyubiquitinated proteins for degradation by either the autophagy or proteasome pathways. The dysregulated
expression and/or activity of p62 in bone disease up-regulates osteoclast functions. This review aims to outline and
summarize the role of p62 in RANKL-induced signaling pathways and in ubiquitin-mediated signaling in
osteoclasts, and the impact of PDB-associated p62 mutations on these processes.
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Background
Encoded by SQSTM1, the ubiquitin-binding protein p62
or sequestosome 1 is a scaffold and an adaptor protein
that modulates protein-protein interactions, and as
major component of multiprotein complexes, it med-
iates various cell functions, including cell signaling,
receptor internalization, protein turnover, and gene
transcription [1]. Mutations of the SQSTM1 gene have
been detected in a high proportion of patients with
Paget’s disease of bone (PDB), thus highlighting the cri-
tical importance of p62 in the regulation of bone phy-
siology [2]. While the most clearly established function
of p62 is its role as a scaffold protein for intracellular
signaling and the selective activation of NF-B [1,3], p62
also plays a major role as a shuttling factor that targets
polyubiquitinated proteins for degradation by either the
autophagy or proteasome pathways [4,5].
Bone remodeling and osteoclast function
Bone remodeling is constant and dynamic, with a bal-
ance maintained between bone resorption and subse-
quent new bone formation. The cells responsible for
these interrelated processes include the bone-resorbing
cells, i.e. osteoclasts, which are derived from hemato-
poietic cells, and bone-formingc e l l s ,i . e .o s t e o b l a s t s ,
which are of mesenchymal origin. Skeletal homeostasis
depends on maintaining tight control of the number of
osteoclasts active at any site [6]. Accelerated or
increased bone resorption may involve elevated osteo-
clastogenesis from precursor cells, an increase in the
fusion and/or activation of osteoclasts, and the prolon-
gation of their lifespan via the inhibition of osteoclast
apoptosis [7,8]. Osteoblasts or stromal cells support
osteoclast differentiation and activation, and these pro-
cesses are regulated by two signaling pathways, which
are activated by M-CSF and receptor activator of NF-B
ligand (RANKL) respectively, and an ITAM (immunore-
ceptor tyrosine-based activation motif)-mediated co-sti-
mulatory signaling [9]. RANKL is a membrane-bound,
TNF-related factor expressed by osteoblast/stromal cells
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d u c eas o l u b l ef o r m .In-vitro and in-vivo studies have
clearly shown that RANKL, by binding to its mem-
brane-bound receptor RANK, plays a crucial role in the
formation, survival, and bone-resorbing activity of osteo-
clasts [10-12]. The fine-tuning of bone resorption also
involves osteoprotegerin (OPG), a secreted decoy recep-
tor of the TNF receptor family expressed by osteoblast/
stromal cells, but also by many other cells in the bone
marrow microenvironment. OPG recognizes RANKL,
and therefore competes with RANK and leads to the
inhibition of osteoclast differentiation and bone-resorp-
tion [13]. After carrying out resorption, osteoclasts
undergo apoptosis. Ordinarily, osteoclasts have been
shown to be sensitive to apoptosis induction by a num-
ber of cytokines and factors, including Fas-ligand,
TRAIL, and TGFb [14-16].
The p62 scaffold, an adaptor protein with multiple
binding domains
The p62 primary sequence embodies at least 9 protein-
interaction domains with structural motifs including a
ubiquitin (Ub)-associated (UBA) domain at its C-termi-
nus, two PEST sequences between which an LC3-inter-
action region (LIR) stands, a binding site for the RING-
finger protein TRAF6, a domain binding p38 as well as
LIM-containing proteins, a ZZ finger interacting with
RIP, a PB1 domain that binds atypical PKCs (aPKCs),
but also ERK, NBR1, MAPKK5 (MEK5), MEKK3, and
p62 itself, and an N-terminus capable of direct interac-
tion with the proteasome (26S and S5a subunits)
[3,17-19](Figure 1-A). With such numerous protein-pro-
tein interaction motifs, p62 is considered a scaffold, ser-
ving as the switchboard from which the RANKL
activation signal is propagated, and thus playing an
important role in the osteoclast.
The p62 scaffold in RANKL-induced signaling
In both precursors and mature osteoclasts, the interac-
tion between RANKL and RANK results in signaling
cascades that ultimately activate transcription factors,
particularly NF-B and NFATc1 [9]. The sequence of
activation requires the recruitment of TRAF6, which is
responsible for most of the downstream events that lead
to osteoclast differentiation and activation [20].
P62 as a functional link between RANKL and TRAF6-
mediated NF-B activation
RANK, like other members of the TNFR family, lacks
the capability for intrinsic enzymatic activity through its
intracellular domain, and relies principally on TNFR
associated factor (TRAF) for signal transduction. The
cytoplasmic domain of RANK directly interacts with five
of the six TRAF proteins, with different binding sites,
that of TRAF6 being more proximal to the membrane
[21,22](Figure 1-B). Three RANK TRAF-binding motifs
have been shown to be involved in the osteoclast forma-
tion and activation, as in the RANK-induced activation
of NF-B and MAP kinases JNK, ERK and p38 [23]. In
addition, TRAF6-specific binding sites have also been
identified, and TRAF6 signaling appears crucial in osteo-
clast signaling [24-26]. The binding of RANKL to its
receptor RANK results in the recruitment of TRAF6;
activated TRAF6 may then stimulate NF-B activity by
activation of the IB kinase (IKK) complex, either
through aPKC or TAK1-dependent phosphorylation, a
process that requires NEMO (IKKg) ubiquitination for
optimal activation [27](Figure 2). The p62 scaffolding
protein is one of the functional links reported between
RANKL and TRAF6-mediated NF-B activation [1].
Once bound to TRAF6, the p62-TRAF6 complex inter-
acts with atypical protein kinase C (aPKC) proteins
resulting in the formation of a multimeric protein com-
plex that regulates NF-B activation via the phosphory-
lation of IBk i n a s eb (IKKb) [28-30]. The p62 complex
also binds the scaffolding receptor interacting protein
(RIP) and phosphoinositide-dependent kinase 1 (PDK1),
recruiting aPKCs to TNF-a signaling complexes [31,32].
TRAF6 also forms complexes with TGFb-activated
kinase 1 (TAK1) and adaptor proteins TAB1 and TAB2
[33]. When TAK1 is activated, it in turn phosphorylates
NF-B-inducing kinase (NIK), which activates the IKK
complex, leading to NF-B pathway activation. As for
the MAP kinases, TAK1 also activates the JNK pathway,
while TAB1 recruits and binds p38 to the TRAF6 com-
plex, leading to activation of its pathway [34,35]. In
addition, RANKL-induced TRAF6 activates the Akt/PKB
pathway through a signaling complex that involves c-Src
[36]. All these signaling molecules contribute to osteo-
clast differentiation, survival and activity [9,20]. As a
scaffold, p62 plays a major role in RANK-induced sig-
naling, through the recruitment and formation of signal-
ing complexes, and its ability to bind and activate
TRAF6 as described below. Confirming the major role
of p62 in the RANK/RANKL signaling pathway, genetic
inactivation of SQSTM1 leads to the inhibition of IKK
and NF-B activation induced by RANKL, as well as
NFATc1 synthesis, and to impaired osteoclastogenesis
in mice [28].
p62 and PDK1/aPKC activation in osteoclasts
In a murine model, RANKL stimulation has been
reported to induce the formation of a ternary complex
between TRAF6, p62 and atypical PKCs (aPKCs), identi-
fying p62 as an important mediator during osteoclasto-
genesis [28]. Consistent with this data, it has also been
shown in human osteoclast cultures that following
RANKL stimulation, PKCζ,P - P K C ζ/l and P-PDK1 as
well were associated to p62 [37]. This is consistent with
the knowledge that PKCζ, like other aPKCs, is a
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aPKC signaling, and perhaps other TRAF6-p62 signaling
pathways. Indeed, PDK1, a serine/threonine kinase, is a
recognized master protein kinase in the regulation of
many cell-signaling pathways, known to be constitutively
active, and can be further activated by tyrosine phos-
phorylation (Tyr
9 and Tyr
373/376). Many proteins
involved in the PI-3K signaling pathway, like PI-3K, Akt,
and the phosphatase and tensin homolog on chromo-
some 10 (PTEN) are mediated by PDK1 [38]. PDK1 has
also been found to phosphorylate and activate other
members of the cAMP-dependent, cGMP-dependent,
and protein kinase C kinase families of proteins includ-
ing both novel and atypical PKCs, p70S6K, and others
[39]. However, its exact role in osteoclast p62 signaling
remains to be elucidated.
The IKK complex is cardinal to the activation of NF-
B, and is composed of three subunits, one of which is
regulatory, called IKKg or NEMO, and two that are cat-
alytic, IKKa and IKKb. Notably, in non-osteoclastic
cells, p62 has been shown to regulate IKK activation
through its ability to bind the atypical PKCs like PKCζ
and PKCl, who favor phosphorylation of IKKb [29,40].
In addition, in PC12 cells, IKKb has been shown to be
recruited to the multiprotein complex including p62,
TRAF6 and aPKC [41].
p62 and the TRAF6/CYLD balance
The protein p62 appears to be a molecular adaptor asso-
ciating not only TRAF6 but also the de-ubiquitinase
CYLD [42]. p62 interactions with TRAF6 stimulate
TRAF6 K63-linked autoubiquitination and E3 ligase
activity, and regulate the synthesis of K63 chains on tar-
get substrates. In addition to the UBA domain, the PB1
domain of p62 is needed for TRAF6 polyubiquitination
[1]. Ubiquitination of TRAF6 is an important mechan-
ism mediating its signaling functions [43,44]. However,
rather than an absolute requirement for TRAF6 E3
ligase activity in mediating downstream signaling, K63-
linked ubiquitination of TRAF6 should be viewed as a
marker of activation [27]. In addition to its well estab-
lished role in the activation of TRAF6, p62 may also
regulate a de-ubiquitinating enzyme (DUB) with a
Figure 1 Interaction motifs and domains of RANKL signal intermediaries.A :p62 and an aPKC. The cytosolic p62 protein, encoded by the
SQSTM1 gene, is a scaffolding protein that interacts with the RANK signaling complex, and is one of the functional links reported between
RANKL and TRAF-6-mediated NF-B activation. Multiple interaction motifs located within p62 enable recruitment of specific proteins and
regulation of downstream signaling pathways. RIP binds to the ZZ domain, whereas TRAF6 interacts with the TF6-b sequence, and the aPKC
isoforms, ERK, and others interact with the PB1 domain. This PB1 interaction directs the aPKCs in the NF-B pathway. The UBA domain binds to
polyubiquitin chains, and is important for the ubiquitination of TRAF6. PB1, PB1 dimerisation domain; ZZ ZNF, ZZ-type zinc finger; TF6-b, TRAF6
binding sequence; PEST, (P, Proline; E, Glutamate; S, Serine; T, Threonine) rich sequence; UBA, ubiquitin associated; PS, pseudosubstrate region;
MATH, meprin and TRAF homology. B: The RANK receptor. RANK has six known putative TRAF-binding motifs (PTM 1-6) of which three have
been involved in osteoclast signaling. TRAF6 binds to membrane-proximal motifs such as PTM3 (PFQEP
369-373), whereas PTM5 (PVQEET
559-564) and
PTM6 (PVQEQ
604-609) most likely interact with TRAF2 and TRAF5 [22,23]. In addition, three other TRAF6- binding sites have been identified, BS I
(PTEDEY
340-345), BS II (PLEVGE
373-378) and BS III (PGEDHE
447-452 [25,26].
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63 (K63) chains (CYLD), that interacts
with TRAF6, and reverses the processing of protein ubi-
quitination. The decrease in the activity of CYLD leads
to the accumulation of Lys
63 (K63)-ubiquitinated sub-
strates [42]. p62 interacts with CYLD and promotes the
binding of CYLD to TRAF6, and this molecular inter-
play requires the C-terminal domain of p62 [45]. CYLD
negatively regulates NF-B activity by reducing TRAF6
autoubiquitination [46,47]. CYLD negatively regulates
the activation of IKK and JNK, and its expression is
markedly upregulated under conditions of RANKL-
induced osteoclastogenesis [45]. Thus CYLD appears to
be a crucial down-regulator of RANK signaling in osteo-
clasts. Accordingly, CYLD-deficient mice display severe
osteoporosis linked to aberrant osteoclast differentiation
and have larger and more numerous osteoclasts, which
are hypersensitive to RANKL [45].
NFATc1 and ERK regulation by p62
RANKL specifically and strongly induces the nuclear
factor of activated T cells (NFATc1 or NFAT2), a mas-
ter regulator of osteoclast differentiation [48]. This
induction is dependent on TRAF6/NF-B and c-Fos
pathways, as well as calcium signaling. NFATc1 also
specifically autoregulates its own promoter particularly
during RANKL-induced osteoclastogenesis [9]. Natu-
rally, TRAF6 activity is affected by p62 interaction,
affording p62 some measure of indirect control over
NFATc1 signaling. However, kinases may also contri-
bute to the nuclear shuttling of this factor, as PKCζ has
been shown to interact with NFATc1, and may modu-
late NFAT-mediated transcription by increasing the
activity of its N-terminal transactivation domain [49]. In
addition, RANKL also induces MEK/ERK pathway
which contributes to osteoclast differentiation and
Figure 2 p62 in osteoclast signaling and protein trafficking. The binding of RANKL to the receptor protein RANK at the plasma membrane
induces the formation of a trimer, triggering the recruitment of a series of adaptor proteins. TRAF6 catalyses Lys63-linked autoubiquitination via
intrinsic E3 ubiquitin ligase activity, which is regulated by the UBA domain of p62, and eventually deubiquitinated post-recruitment of CYLD to
p62. In the interim, this ubiquitination permits activation of the TAB1-TAB2-TAK1 complex, in turn activating the MAP kinases, as well as NF-B-
inducing kinase (NIK), which leads to phosphorylation and activation of IKKb. Activation of TRAF6 and p62 also leads to activation of the Akt/PKB
pathway. Simultaneously, p62 binds aPKC through its N-terminal PB1, allowing for the phosphorylation of IKKb by the aPKC. Once activated, IKKb
phosphorylates IB, which is subsequently ubiquitinated, and degraded through the proteasome system, liberating NF-B to translocate to the
nucleus and interact with transcription promoters.
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role in the activation of NF-B, NFAT and in ERK
phosphorylation [51].
Role of p62 in protein trafficking and turnover
P62 and protein turnover
The signal for targeting proteins for degradation by
either the autophagy or proteasome pathways is ubiqui-
tination, both processes in which p62 plays a major role
through binding ubiquitinated protein and trafficking as
w e l l .p 6 2m a yb ei n v o l v e di nt h ef o r m a t i o no fm u l t i -
meric protein complexes as a result of the interactions
of its PB1 domain with other proteins, and it may also
p l a yar o l ei np r o t e i nt u r n o v e ra sar e s u l to fi t sU B A
domain at its C-terminus, which binds non-covalently to
polyubiquitin chains, and finally through its association
w i t ht h ep r o t e a s o m e( 2 6 Sa n dS 5 as u b u n i t s )v i ai t sN -
terminus domain [19]. In a well-characterized neuronal
model, p62 has been shown to direct the addressing of
protein complexes containing the neurotrophin recep-
tors, TRAF6, and PKCζ, making it an essential player in
signaling protein degradation and recycling [52,53].
Autophagy and LC3 interaction
Autophagy takes place in all cells, in order to maintain
cell homeostasis or in response to stress or starvation,
by eliminating damaged components, and providing
cells with energy and nutrient resourcing [54,55]. p62
has been identified as an LC3-interacting protein impli-
cated in autophagy [56-58]. Studies have shown that
p62, along with ubiquitinated proteins, is transported
into autophagosomes, suggesting that p62 is a receptor
for these proteins that directs them to lysosomes
[56,58]. This is made possible by its LRS (LC3 recogni-
tion sequence) located between the zinc finger and UBA
domains of p62, where residues interact with the N-ter-
minus and ubiquitin domain of LC3 [59,60]. Interest-
ingly, knockout of p62 does not appear to markedly
affect levels of ubiquitinated proteins in the cell, possibly
due to compensatory action by Nbr1 (neighbor of
BRCA1 gene 1), which interacts with LC3 in a similar
manner [57,61]. Loss of function of Nbr1 leads to per-
turbation of p62 levels and hyperactivation of p38
MAPK that favors osteoblastogenesis [62]. Autophagy
has been involved in hypoxia-induced osteoclast differ-
entiation [63], and p62 may play a role in the starva-
tion-induced autophagy in human osteoclasts [4].
p62 and molecular cross-talk between apoptosis and
autophagy
The consequences of autophagy mainly favor cell survi-
val, although a complex crosstalk exists between autop-
hagy and apoptosis pathways [55]. While p62 has been
involved in the selective autophagic degradation of
many proteins, p62 is also involved in several apoptotic
and survival pathways. RANKL stimulation contributes
to osteoclast survival through p62-driven activation of
NF-B and MEK/ERK pathways [51]. Conversely, p62
also interacts with caspase-8, and is crucial for efficient
caspase-8 activation by promoting aggregation of cullin-
3 mediated-polyubiquitination [64]. On the other hand,
p62 may be cleaved by caspase-6 and -8 in response to
death receptor activation [65], and caspase-8, as well as
p62, may be degraded by autophagy [66]. Thus, interre-
lationships exist between autophagy that affect the effi-
ciency of apoptosis, and apoptosis that affects p62-
dependent autophagy [55].
Impact of PDB-associated p62 mutations on osteoclasts
Paget’s disease of bone (PDB) is characterized by focal
and disorganized increases in bone turnover, and pri-
marily affects osteoclasts [67]. The role of p62 as an
important modulator of bone turnover has first been
highlighted by the discovery of mutations of the
SQSTM1 gene in numerous pagetic patients, the
p62
P392L substitution being the most frequent.
Impact of the p62
P392L mutation on osteoclast signaling
T h es i g n i f i c a n c eo ft h ep 6 2
P392L mutation has been stu-
died in a series of in-vitro experiments, using osteoclast
precursors derived from the peripheral blood of PDB
patients carrying the p62
P392L gene, and from bone mar-
row cells or cord blood monocytes (CBM) of normal
subjects transfected with the wild-type p62 (p62
wt)o r
the p62
P392L gene. These osteoclast precursors are
hyper-responsive to osteoclastogenic factors, such as
RANKL and TNFa,a n dt h ep 6 2
P392L-transfected cells
have an enhanced ability to resorb bone [68]. Trans-
g e n i cm i c ee x p r e s s i n gt h ep 6 2
P394L gene (p62
P392L
equivalent in human) develop PDB-like bone lesions
[ 6 9 ] ,a st r a n s g e n i cm i c ec o e x p r e s s i n gt h em e a s l e sv i r u s
nucleocapsid (MVNP) under the TRAP promoter and
knocked-in p62
P394L [ 7 0 ] .P r e v i o u sf i n d i n g sh a v e
revealed that in human osteoclasts, even prior to
RANKL stimulation, p62 associates with both activated
PDK1 and PKCζ or activated PKCζ/l in PDB osteo-
clasts, in osteoclasts from healthy donors harboring the
p62
P392L gene, and in p62
P392L transfected osteoclasts
[37]. Although both wild-type and mutated p62 over-
expression favors the formation of activated PKCζ/l-p62
complexes, only that of the mutated gene led to an
increased basal level of NF-B activation [37]. Similarly,
overexpression of the p62
P392L mutant in HEK293 or
Cos-1 cells increases basal and RANKL-induced NF-B
activation, more than overexpression of the wild-type
p62 [71]. Finally, the presence of the PDB-associated
p62
P392L mutation upregulates NFATc1 expression in
pre-osteoclasts, favoring the increased osteoclastogenesis
and osteoclast activity associated with metabolic bone
disease [28,72]. These findings strongly suggest that
p62
P392L contributes at least in part to the induction of
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pathways. More recent studies have further confirmed
that CYLD knockdown significantly increased c-Fos
expression in cells transduced to express both wild-type
and mutant p62, without necessitating RANKL stimula-
tion. Likewise, mutations to the UBA domain of p62
lead to a reduction in CYLD activity, and thus an
increase in osteoclast development and resorption [72].
Impact of the p62
P392L mutation on protein turnover
All of the mutations identified to date in PDB patients
are clustered either within or near the C-terminal region
of the p62 protein that embodies the ubiquitin-asso-
ciated (UBA) domain, and affect its interactions with
multiubiquitin chains, suggesting that an alteration of
ubiquitin-chain binding by p62 is important in the
development of PDB [73,74]. The accumulation of p62-
associated proteins, due to impaired degradation
through proteosomal or autophagic pathways, could
explain some aberrant cellular functions. As p62 is a key
player in selective autophagy, and may have a role in
the formation of inclusion bodies [53,57], and because
the inclusion bodies found in Pagetic osteoclasts resem-
ble those observed in diseases with defective autophagy,
a dysregulation of the autophagy process may well be
part of the pathogeny in PDB, although so far no direct
evidence has been provided for its role in the phenotype
of Pagetic osteoclast [75]. In addition, the p62
P392L
mutation did not affect the p62-related aggregate forma-
tion in human osteoclasts [4].
Osteoclast apoptosis in PDB
In osteoclast cultures derived from PDB patients it has
been observed that lower rates of apoptosis are
induced by the deprivation of survival factors or by
death inducers, such as TRAIL, Fas activating antibody
or TGF-b [37]. In CBMs cultures, apoptosis rates are
lower in osteoclasts overexpressing either p62
wt or
p62
P392L than in controls. Furthermore, it has been
shown that p62 is overexpressed in PDB osteoclasts,
and this could contribute to their resistance to apopto-
sis, given that increased expression of p62 could in
itself have a protective effect against cell death by pre-
venting the build-up of potentially cell-damaging pro-
teins [56,76]. In addition, the basal and RANKL-
induced activation of NF-B may influence survival in
PDB osteoclasts. Finally, some genes involved in osteo-
clast apoptosis (encoding Caspase-3, and TRAIL-R1)
are downregulated in Pagetic osteoclasts [77], and the
expression of anti-apoptotic Bcl-2 gene is upregulated
[78]. So, while it is clear that apoptosis is hindered in
PDB osteoclasts, and that the presence of PDB muta-
tions in the p62 gene is involved in this, the mechan-
isms by which these apoptotic pathways are altered are
still unknown.
Conclusions
Overproduction or changes in p62 activity has been
shown to lead to impaired signaling and deficient autop-
hagy in other cell and receptor models [57]. The prob-
ability remains that the same buildup of p62 and/or
faulty UBA activity may be responsible for increased
p62 substrate activity, and simultaneous reduced shut-
tling/ubiquitin-related activity, altering feedback and sig-
naling loops. Since recent data also support the notion
that p62 acts as a conformational adaptor, linking sub-
strates from one domain to substrates bound to another,
and not just the proteasome, p62 affects the cell in more
ways than degradation and shuttling [5,79]. Given the
number of mechanisms regulated either directly or
indirectly by p62, its importance to osteoclast activation
is unquestionable; playing an intimate role in protein
signaling, polyubiquitination, and trafficking. The exact
breadth of the influence of p62 in the osteoclast remains
to be fully identified, and thus this RANKL regulator
and its substrates provide targets of interest for explora-
tion in order to better understand osteoclast activation
signaling.
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